TEVA Stock Analysis: Teva Pharma Industries | NYSE
Drug Manufacturers - Specialty & Generic | NYSE, USA | Market Cap: 46.430m USD | 12M Return: 96% | US8816242098 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 193M
EPS Trend: 71.3%
Qual. Beats: 1
Rev. Trend: 93.8%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Teva Pharmaceutical Industries is an Israeli-based global pharmaceutical company that develops, manufactures, and markets both generic medicines and branded biopharmaceutical products across the United States, Europe, Israel, and other international markets. Founded in 1901 and headquartered in Tel Aviv-Yafo, the company operates one of the worlds largest generic drug portfolios, offering medicines in tablets, capsules, injectables, inhalants, and other dosage forms, alongside active pharmaceutical ingredients and contract manufacturing services.
The companys branded biopharmaceutical business focuses on central nervous system (CNS), respiratory, and oncology therapeutics, with key products including COPAXONE for multiple sclerosis, AJOVY for migraine prevention, AUSTEDO for tardive dyskinesia and Huntingtons chorea, UZEDY for schizophrenia, and BENDEKA/TREANDA for certain leukemia and lymphoma indications. Teva also markets respiratory products such as QVAR RediHaler, ProAir RespiClick, and AirDuo RespiClick, and operates an out-licensing platform that monetizes its product portfolio through partnerships with other pharmaceutical companies.
The generic drug industry is characterized by intense price competition and ongoing consolidation, while the specialty/branded biopharmaceutical segment typically carries higher margins and longer product life cycles through patent protection. Teva maintains collaboration and licensing agreements with partners including MedinCell, Sanofi, Alvotech, Biolojic Design, and MODAG, supporting its dual business model of high-volume generics and higher-margin specialty therapeutics.
- Austedo sales surge offset Copaxone generic erosion
- Debt reduction accelerates as free cash flow expands
- Opioid litigation settlement costs pressure margins
| Net Income: 706.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 1.16 > 1.0 |
| NWC/Revenue: -10.89% < 20% (prev 4.56%; Δ -15.46% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.90b > Net Income 706.0m |
| Net Debt (13.5b) to EBITDA (2.59b): 5.20 < 3 |
| Current Ratio: 0.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.18b) vs 12m ago 1.72% < -2% |
| Gross Margin: 52.45% > 18% (prev 49.60%; Δ 2.85% > 0.5%) |
| Asset Turnover: 43.29% > 50% (prev 41.43%; Δ 1.86% > 0%) |
| Interest Coverage Ratio: 1.78 > 6 (EBIT TTM 1.60b / Interest Expense TTM 902.0m) |
| A: -0.05 (Total Current Assets 13.8b - Total Current Liabilities 15.6b) / Total Assets 39.9b |
| B: -0.35 (Retained Earnings -14.0b / Total Assets 39.9b) |
| C: 0.04 (EBIT TTM 1.60b / Avg Total Assets 40.0b) |
| D: 0.24 (Book Value of Equity 7.76b / Total Liabilities 32.1b) |
| Altman-Z'' = -0.93 = CCC |
| DSRI: 0.94 (Receivables 3.49b/3.56b, Revenue 17.3b/16.6b) |
| GMI: 0.95 (GM 49.60% / 52.45%) |
| AQI: 0.98 (AQ_t 0.55 / AQ_t-1 0.56) |
| SGI: 1.04 (Revenue 17.3b / 16.6b) |
| TATA: -0.03 (NI 706.0m - CFO 1.90b) / TA 39.9b) |
| Beneish M = -3.11 (Cap -4..+1) = AA |
As of October 01, 2026, the stock is trading at USD 39.60 with a total of 5,654,529 shares traded. Over the past week, the price has changed by +1.51%, over one month by +9.85%, over three months by +16.88% and over the past year by +96.04%.
Current recommended Stop Loss: 36.70 (which is 7.3% or 2.3 ATR below the current price).
Teva Pharma Industries has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy TEVA.
- StrongBuy: 6
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 43.7 | 10.3% |
P/E Trailing = 65.2623
P/E Forward = 7.0472
P/S = 2.6815
P/B = 3.3623
P/EG = 1.2867
Revenue TTM = 17.3b USD
EBIT TTM = 1.60b USD
EBITDA TTM = 2.59b USD
Long Term Debt = 12.1b USD (from longTermDebt, last quarter)
Short Term Debt = 4.50b USD (from shortTermDebt, last quarter)
Debt = 17.2b USD (from shortLongTermDebtTotal, last quarter) + Leases 282.0m
Net Debt = 13.5b USD (calculated: Debt 17.2b - CCE 3.65b)
Enterprise Value = 59.9b USD (46.4b + Debt 17.2b - CCE 3.65b)
Interest Coverage Ratio = 1.78 (Ebit TTM 1.60b / Interest Expense TTM 902.0m)
EV/FCF = 44.46x (Enterprise Value 59.9b / FCF TTM 1.35b)
FCF Yield = 2.25% (FCF TTM 1.35b / Enterprise Value 59.9b)
FCF Margin = 7.79% (FCF TTM 1.35b / Revenue TTM 17.3b)
Net Margin = 4.08% (Net Income TTM 706.0m / Revenue TTM 17.3b)
Gross Margin = 52.45% ((Revenue TTM 17.3b - Cost of Revenue TTM 8.23b) / Revenue TTM)
Gross Margin QoQ = 51.98% (prev 49.49%)
Tobins Q-Ratio = 1.50 (Enterprise Value 59.9b / Total Assets 39.9b)
Interest Expense / Debt = 5.26% (Interest Expense 902.0m / Debt 17.2b)
Taxrate = 1.67% (12.0m / 720.0m)
NOPAT = 1.58b (EBIT 1.60b * (1 - 1.67%))
Current Ratio = 0.88 (Total Current Assets 13.8b / Total Current Liabilities 15.6b)
Debt / Equity = 2.21 (Debt 17.2b / totalStockholderEquity, last quarter 7.76b)
Debt / EBITDA = 5.20 (Net Debt 13.5b / EBITDA 2.59b)
Debt / FCF = 10.02 (Net Debt 13.5b / FCF TTM 1.35b)
Total Stockholder Equity = 7.79b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.77% (Net Income 706.0m / Total Assets 39.9b)
RoE = 9.07% (Net Income TTM 706.0m / Total Stockholder Equity 7.79b)
RoCE = 8.07% (EBIT 1.60b / Capital Employed (Equity 7.79b + L.T.Debt 12.1b))
RoIC = 5.67% (NOPAT 1.58b / Invested Capital 27.8b)
WACC = 6.35% (E(46.4b)/V(63.6b) * Re(6.79%) + D(17.2b)/V(63.6b) * Rd(5.26%) * (1-Tc(0.02)))
Discount Rate = 6.79% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.06 | Cagr: 2.26%
[DCF] Terminal Value 77.97% ; FCFF base≈1.16b ; Y1≈1.34b ; Y5≈1.97b
[DCF] Fair Price = 13.78 (EV 29.6b - Net Debt 13.5b = Equity 16.1b / Shares 1.17b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 71.31 | EPS CAGR: 5.86% | SUE: 4.0 | # QB: 1
Revenue Correlation: 93.80 | Revenue CAGR: 4.07% | SUE: 0.74 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.68 | Chg30d=N/A | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=2.15 | Chg30d=N/A | Revisions=+0% | GrowthEPS=-29.5% | GrowthRev=-3.5%
EPS next Year (2027-12-31): EPS=3.05 | Chg30d=N/A | Revisions=+0% | GrowthEPS=+42.0% | GrowthRev=+3.9%
[Analyst] Revisions Ratio: +0% (up=0, down=0)